At late stages the amount of insoluble Tau in the P301L model is comparable to symptomatic human AD patients (Braak stage IV-V) (~ 1000 fmol/mg), while the P301S model shows 4 × less insoluble Tau (~ 250 fmol/mg). Here, MAPT is linked to Alzheimer disease.